MA31352B1 - Dérivés imidazolidine carboxamide comme modulateurs de p2x7. - Google Patents

Dérivés imidazolidine carboxamide comme modulateurs de p2x7.

Info

Publication number
MA31352B1
MA31352B1 MA32245A MA32245A MA31352B1 MA 31352 B1 MA31352 B1 MA 31352B1 MA 32245 A MA32245 A MA 32245A MA 32245 A MA32245 A MA 32245A MA 31352 B1 MA31352 B1 MA 31352B1
Authority
MA
Morocco
Prior art keywords
pain
receptor
imidazolidin
carboxamide derivatives
compounds
Prior art date
Application number
MA32245A
Other languages
Arabic (ar)
English (en)
Inventor
Paul John Beswick
David Kenneth Dean
Robert James Gleave
Andrew Peter Moses
Daryl Simon Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0706501A external-priority patent/GB0706501D0/en
Priority claimed from GB0720653A external-priority patent/GB0720653D0/en
Priority claimed from GB0805272A external-priority patent/GB0805272D0/en
Priority claimed from GB0805504A external-priority patent/GB0805504D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31352B1 publication Critical patent/MA31352B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci. Les composés ou les sels modulent la fonction récepteur de p2x7 et peuvent antagoniser les effets de atp au niveau du récepteur de p2x7 (antagonistes du récepteur de p2x7). L'invention concerne également l'utilisation de ces composés ou sels, ou des compositions pharmaceutiques de ceux-ci dans le traitement ou la prévention de troubles/maladies médiés par le récepteur de p2x7, par exemple la douleur, l'inflammation ou une maladie neurodégénérative, en particulier la douleur telle que la douleur inflammatoire, la douleur neuropathique ou la douleur viscérale.
MA32245A 2007-04-03 2009-10-02 Dérivés imidazolidine carboxamide comme modulateurs de p2x7. MA31352B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0706501A GB0706501D0 (en) 2007-04-03 2007-04-03 Novel compounds
GB0720653A GB0720653D0 (en) 2007-10-22 2007-10-22 Novel compounds
GB0805272A GB0805272D0 (en) 2008-03-20 2008-03-20 Novel compounds
GB0805504A GB0805504D0 (en) 2008-03-26 2008-03-26 Compounds
PCT/EP2008/053962 WO2008119825A2 (fr) 2007-04-03 2008-04-02 Dérivés imidazolidine carboxamide comme modulateurs de p2x7

Publications (1)

Publication Number Publication Date
MA31352B1 true MA31352B1 (fr) 2010-05-03

Family

ID=39673302

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32245A MA31352B1 (fr) 2007-04-03 2009-10-02 Dérivés imidazolidine carboxamide comme modulateurs de p2x7.

Country Status (15)

Country Link
US (1) US7932282B2 (fr)
EP (1) EP2142512A2 (fr)
JP (1) JP2010523524A (fr)
KR (1) KR20090127435A (fr)
CN (1) CN101679291A (fr)
AU (1) AU2008234855B2 (fr)
BR (1) BRPI0809930A2 (fr)
CA (1) CA2682649A1 (fr)
CR (1) CR11089A (fr)
DO (1) DOP2009000231A (fr)
EA (1) EA200970912A1 (fr)
IL (1) IL201202A0 (fr)
MA (1) MA31352B1 (fr)
MX (1) MX2009010759A (fr)
WO (1) WO2008119825A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271182B2 (en) * 2006-07-06 2012-03-15 Glaxo Group Limited Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
CA2768396A1 (fr) * 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Amides de dihydropyrimidone utilises comme modulateurs p2x7
CN104623665B (zh) 2009-12-08 2018-01-12 范德比尔特大学 用于静脉采集和自体移植的改进的方法和组合物
US20130195919A1 (en) 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
WO2012110190A1 (fr) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Nouveaux antagonistes p2x7r et leur utilisation
EP2681200A4 (fr) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd Inhibiteurs de type benzimidazole du canal sodique
WO2012163456A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2012163792A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
AR087274A1 (es) 2011-07-22 2014-03-12 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7
WO2013108227A1 (fr) 2012-01-20 2013-07-25 Actelion Pharmaceuticals Ltd Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
AU2013356850B2 (en) 2012-12-12 2018-02-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonists
CN104854087B (zh) 2012-12-18 2017-03-22 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104918617B (zh) 2013-01-22 2017-05-10 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
CN104918946B (zh) 2013-01-22 2017-03-29 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US11180484B2 (en) 2016-05-31 2021-11-23 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
SI3716952T1 (sl) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
EP4010333A1 (fr) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
JP7323723B2 (ja) * 2020-06-17 2023-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
CN115650920B (zh) * 2022-11-16 2023-03-31 山东金城柯瑞化学有限公司 制备药物中间体(4s)-1-甲基-2-氧代咪唑啉-4-羧酸叔丁酯的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5024287A (fr) 1973-06-28 1975-03-15
JP2830528B2 (ja) 1991-07-25 1998-12-02 東洋インキ製造株式会社 シート状物保持装置
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB0324498D0 (en) * 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
AU2007271182B2 (en) 2006-07-06 2012-03-15 Glaxo Group Limited Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use

Also Published As

Publication number Publication date
IL201202A0 (en) 2010-05-17
MX2009010759A (es) 2009-10-28
WO2008119825A3 (fr) 2008-12-11
EA200970912A1 (ru) 2010-02-26
CA2682649A1 (fr) 2008-10-09
AU2008234855A1 (en) 2008-10-09
CR11089A (es) 2010-03-08
WO2008119825A2 (fr) 2008-10-09
EP2142512A2 (fr) 2010-01-13
CN101679291A (zh) 2010-03-24
US7932282B2 (en) 2011-04-26
AU2008234855B2 (en) 2011-01-20
US20100075968A1 (en) 2010-03-25
KR20090127435A (ko) 2009-12-11
DOP2009000231A (es) 2009-11-15
BRPI0809930A2 (pt) 2014-10-07
JP2010523524A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
MA31352B1 (fr) Dérivés imidazolidine carboxamide comme modulateurs de p2x7.
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation
DE602008005582D1 (de) Pyrazolderivate als p2x7-modulatoren
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
WO2009106980A3 (fr) Dérivés d'indazole
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA35576B1 (fr) Nouveaux composés
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA33552B1 (fr) Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
WO2008125600A3 (fr) Dérivés de pyrazole utilisés comme modulateurs de p2x7
WO2008119685A3 (fr) Dérivés d'oxazolidine et de morpholine carboxamide comme modulateurs de p2x7
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
WO2008130879A3 (fr) Dérivés de tétrahydroindole et de tétrahydroindazole
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma